Vestmark Advisory Solutions Inc. purchased a new position in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 8,405 shares of the medical research company's stock, valued at approximately $472,000.
Several other hedge funds and other institutional investors have also modified their holdings of EXAS. Asset Management One Co. Ltd. increased its position in shares of Exact Sciences by 4.3% during the third quarter. Asset Management One Co. Ltd. now owns 68,615 shares of the medical research company's stock worth $4,674,000 after acquiring an additional 2,837 shares during the period. AIA Group Ltd boosted its stake in Exact Sciences by 7.6% in the third quarter. AIA Group Ltd now owns 30,731 shares of the medical research company's stock valued at $2,093,000 after acquiring an additional 2,179 shares in the last quarter. Capital Performance Advisors LLP acquired a new position in Exact Sciences during the third quarter worth approximately $35,000. Atria Investments Inc acquired a new stake in Exact Sciences during the 3rd quarter worth $244,000. Finally, Axxcess Wealth Management LLC acquired a new stake in Exact Sciences during the 3rd quarter worth $243,000. 88.82% of the stock is currently owned by hedge funds and other institutional investors.
Exact Sciences Trading Up 1.0 %
Shares of EXAS traded up $0.46 during trading hours on Wednesday, hitting $46.35. The stock had a trading volume of 1,524,745 shares, compared to its average volume of 2,322,006. The company's fifty day simple moving average is $52.45 and its 200 day simple moving average is $59.15. Exact Sciences Co. has a 12-month low of $40.62 and a 12-month high of $79.62. The company has a debt-to-equity ratio of 0.97, a quick ratio of 1.93 and a current ratio of 2.15. The firm has a market cap of $8.61 billion, a P/E ratio of -8.32 and a beta of 1.25.
Exact Sciences (NASDAQ:EXAS - Get Free Report) last posted its earnings results on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.29) by $0.23. The firm had revenue of $713.42 million during the quarter, compared to the consensus estimate of $701.45 million. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 5.29%. Equities research analysts forecast that Exact Sciences Co. will post -0.58 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Several equities analysts recently issued reports on the company. Piper Sandler dropped their price target on Exact Sciences from $75.00 to $70.00 and set an "overweight" rating on the stock in a research report on Wednesday, February 26th. William Blair reissued an "outperform" rating on shares of Exact Sciences in a report on Thursday, February 20th. Barclays decreased their price target on Exact Sciences from $70.00 to $65.00 and set an "overweight" rating for the company in a report on Thursday, February 20th. BTIG Research boosted their price objective on shares of Exact Sciences from $65.00 to $75.00 and gave the company a "buy" rating in a research note on Tuesday, November 26th. Finally, Bank of America lowered their target price on shares of Exact Sciences from $72.00 to $65.00 and set a "buy" rating on the stock in a report on Thursday, February 20th. One equities research analyst has rated the stock with a hold rating and eighteen have given a buy rating to the company's stock. Based on data from MarketBeat, Exact Sciences currently has an average rating of "Moderate Buy" and an average price target of $71.94.
Get Our Latest Analysis on EXAS
Exact Sciences Company Profile
(
Free Report)
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.
See Also
Before you consider Exact Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exact Sciences wasn't on the list.
While Exact Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
